Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Ryplazim Coverage Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Ryplazim (plasminogen, human-tvmh) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Part B coverage and prior authorization criteria for Ryplazim in patients with plasminogen deficiency type 1 (hypoplasminogenemia).

    Policy Summary
    PayerGold Coast Health Plan
    PolicyRyplazim (plasminogen, human-tvmh) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit baseline plasminogen activity of 45% or less, current weight, and genetic testing confirming plasminogen deficiency type 1.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6.6 mg/kgRecommended dose
    Every 2-4 daysAdministration frequency
    ≤45%Baseline activity threshold
    12 monthsReauthorization interval
    J2998

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HCPCS billing code
    1 mgBilling unit

    Coverage Criteria

    Initial Therapy

    Initial therapy is covered when ALL of the following criteria are met:

    ALL of the following

    • Patient has plasminogen deficiency type 1 (hypoplasminogenemia).
    • Documentation of a baseline plasminogen activity level of ≤45%.
    • Genetic testing confirms the diagnosis of plasminogen deficiency type 1.
    • Ryplazim is prescribed at 6.6 mg/kg based on the patient's current weight and administered every two to four days, consistent with the FDA-approved indication.
    • Ryplazim is prescribed by or in consultation with a hematologist.
    • No exclusion criteria apply.

    Reauthorization

    Continuation coverage is available for 12 months when the patient continues to meet applicable coverage criteria.

    ALL of the following

    • Continuation of Ryplazim therapy is requested.
    • Dose is consistent with FDA-approved labeling or accepted standards of medical practice.

    Coding and Administration

    Covered HCPCS CodesHCPCSCovered
    J2998Ryplazim (plasminogen, human-tvmh)
    Baseline plasminogen activity
    Required baseline activity45% or less
    Test purposeDocuments the patient's plasminogen activity before treatment
    Submission requirementInclude the baseline plasminogen activity level with the coverage request
    Ryplazim dose
    Recommended dose6.6 mg/kg body weight
    MedicationRyplazim (plasminogen, human-tvmh)
    Dosing basisWeight-based administration

    Prior Authorization and Provider Requirements

    Prior Authorization

    Submit initial prior authorization documentation

    Prior authorization requires documentation of plasminogen deficiency type 1 (hypoplasminogenemia), including a baseline plasminogen activity level of 45% or less and genetic testing confirming the diagnosis.

    Documentation Required

    Provide required medical information

    Submit the patient's baseline plasminogen activity level, which must be documented at 45% or less, the patient's current weight, and genetic testing confirming plasminogen deficiency type 1.

    Background

    Ryplazim (plasminogen, human-tvmh) is a plasma-derived human plasminogen formulation indicated for the treatment of patients with plasminogen deficiency type 1, also known as hypoplasminogenemia. The policy describes administration at 6.6 mg/kg body weight every two to four days.

    Definitions

    Plasminogen deficiency type 1
    DefinitionA plasminogen deficiency disorder
    Alternate nameHypoplasminogenemia
    Covered treatmentRyplazim is indicated for patients with this condition
    Baseline plasminogen activity level
    DefinitionThe patient's measured plasminogen activity before treatment
    Policy threshold45% or less
    DocumentationThe baseline activity level must be documented for coverage review

    Initial Therapy

    Initial Therapy Criteria

    Ryplazim is covered for the treatment of patients with plasminogen deficiency type 1 when all required documentation and prescriber criteria are met.

    Initial coverage requirements

    • Document plasminogen deficiency type 1 (hypoplasminogenemia).
    • Document a baseline plasminogen activity level of 45% or less.Baseline plasminogen activity ≤45%
    • Provide genetic testing confirming the diagnosis.
    • Provide the patient's current weight.

    Continuation and Reauthorization

    Continuation Criteria

    Reauthorization is available for 12 months.

    Continuation of Ryplazim

    • Request reauthorization after the applicable authorization period.
    • Maintain dosing according to FDA-approved labeling or accepted standards of medical practice.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyRyplazim (plasminogen, human-tvmh) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit baseline plasminogen activity of 45% or less, current weight, and genetic testing confirming plasminogen deficiency type 1.
    SourceLink
    On This Page
    Coverage CriteriaCoding and AdministrationPrior Authorization and Provider RequirementsBackgroundDefinitionsInitial TherapyContinuation and Reauthorization
    Administration frequency
    Administration frequencyEvery two to four days
    Administration scheduleAdministered repeatedly at two- to four-day intervals
    Applies toRyplazim treatment for plasminogen deficiency type 1
    Denial Risk

    Meet all clinical coverage criteria

    Coverage may be denied when the patient does not have documented plasminogen deficiency type 1, baseline plasminogen activity is above 45% or undocumented, genetic confirmation is missing, or the requested dose is outside FDA-approved labeling or accepted standards of medical practice.

    Denial Risk

    Confirm hematologist involvement

    Coverage may be denied when Ryplazim is not prescribed by or in consultation with a hematologist.

    Ensure prescription by or consultation with a hematologist.